An interventional study of 12-week Intervention Period and 12-week Observation Period in Breast Cancer, sponsored by University of Florida. Completed at 1 site in United States. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by University of Florida · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Breast Neoplasms by University of Florida — 9 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · University of Florida.
Among the 22 studies in Breast Neoplasms by University of Florida, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 14 with no phase, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 22 studies in Breast Neoplasms by University of Florida are open now, in 1 country. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–100
University of Florida · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–100 · Healthy volunteers
University of Florida · Sites in United States
Ages 18–80 · Women only
University of Florida · Sites in United States
Ages 18–99
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4
First in 2012; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 28 across the 18 interventional studies, 33 across the 4 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
6 of the studies in Breast Neoplasms by University of Florida that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05000294University of FloridaAtezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | 2026-12 |
| NCT05074290University of FloridaPharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients | 2026-12 |
| NCT04914663University of FloridaAll-extremity Exercise During Breast Cancer Chemotherapy | 2027-01-31 |
| NCT07042243University of FloridaThe Florida ASCENT Study | 2027-08 |
| NCT05655494University of FloridaA Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 22 studies in Breast Neoplasms by University of Florida, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Supervised home-based high-intensity interval training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
Behavioral: 12-week Intervention Period · Behavioral: 12-week Observation Period
Supervised home-based moderate-intensity continuous training will be performed on an all-extremity stationary cycle 3 days/week for 12 weeks.
Behavioral: 12-week Intervention Period · Behavioral: 12-week Observation Period
Research participants will continue their habitual physical activity for the duration of the study. Once they complete the study, they will have the opportunity to perform supervised HIIT or MICT at home for 3 days/week for 12 weeks (research participants can choose either type of exercise).
Behavioral: 12-week Intervention Period · Behavioral: 12-week Observation Period
Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
Change in brachial FMD
Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia.
Time frame: Baseline, Following a 12-week intervention period, Following a 12-week observation period
Change in cardiac function (global longitudinal strain)
Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction.
Time frame: Baseline, Following a 12-week intervention period, Following a 12-week observation period
Percent completed vs. planned exercise frequency
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week.
Time frame: Throughout the 12 weeks of supervised home-based exercise training
Percent completed vs. planned exercise duration
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session.
Time frame: Throughout the 12 weeks of supervised home-based exercise training
Percent completed vs. planned exercise intensity
The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session.
Time frame: Throughout the 12 weeks of supervised home-based exercise training
Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise intervention
To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions.
Time frame: Throughout the 12 weeks of supervised home-based exercise training
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2024 to primary completion in May 2026, 26 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 26 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Dec 2026 → May 2026 and completion Dec 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.